5-Amino-1MQ is not a peptide: what NNMT inhibition is, and how far the work goes

Almost every research catalogue in Canada lists 5-Amino-1MQ under 'peptides'. It is not one. 5-Amino-1-methylquinolinium is a quinolinium small molecule — one fused ring system with a methylated nitrogen, molecular weight around 159 g/mol, CAS 42464-96-0 for the iodide salt. No amide backbone, no amino acid sequence, none of the things that make a peptide a peptide.

The distinction is not pedantry. It decides how the molecule behaves in the gut, which formats it can be sold in, and which of the assumptions a buyer carries over from peptides are wrong.

The enzyme

5-Amino-1MQ is studied as an inhibitor of nicotinamide N-methyltransferase — NNMT. That enzyme takes nicotinamide, the precursor cells use to rebuild NAD+, and methylates it to 1-methylnicotinamide, which is then excreted. Every molecule that leaves by that route is one that does not re-enter the NAD+ salvage pathway.

NNMT sits at low levels in most tissues. It is markedly elevated in white adipose tissue in obese models, and elevated again in several tumour types. The research question follows directly from that asymmetry: block the enzyme, and does the nicotinamide pool redirect toward NAD+ synthesis in the tissue where the enzyme was overexpressed, and does cellular energy metabolism there change as a result.

That is the question the literature asks. It is not the same as the question a buyer usually arrives with.

What three papers reported

Kraus and colleagues knocked NNMT down with an antisense oligonucleotide in diet-induced obese mice and reported protection against weight gain together with improved insulin sensitivity (PMID 24717514). This is the paper that made NNMT a metabolic target, and it did so before any small-molecule inhibitor existed — the knockdown is genetic, not pharmacological.

Neelakantan and colleagues then developed membrane-permeable small-molecule NNMT inhibitors — the class 5-Amino-1MQ belongs to — and reported reduced adiposity in the same diet-induced obesity model (PMID 29155147). Kannt and colleagues extended the approach with a separate inhibitor series against metabolic syndrome endpoints (PMID 33668468).

Two things about that body of work deserve stating plainly rather than in a footnote.

It is preclinical. Mice and cell culture, nothing else.

And the molecule in the paper is frequently not this molecule. Much of the inhibitor work uses other members of the same chemical class. What is reasonably well characterised is the mechanism — inhibit NNMT, spare nicotinamide, watch the NAD+-dependent biology downstream. What is less well characterised is 5-Amino-1MQ itself, which inherits most of its reputation from its neighbours.

Why the category error survives

Three reasons, none of them good. It is sold by the companies that sell peptides. It arrives as a lyophilised powder in a glass vial, which is what peptides look like. And the research around it — NAD+ metabolism, adipose biology — shares shelf space with peptide research.

The practical consequence is that buyers apply peptide reasoning to it, and one of those inferences matters. Peptides are cleaved by gastric proteases, which is why they are studied parenterally and why an oral peptide product is usually a tell. 5-Amino-1MQ has no peptide bonds to cleave. That is the whole reason oral formulations of it exist, and the reason '5-amino-1mq capsules' is a real search while 'BPC-157 capsules' is mostly a scam signal.

Vial or capsule

Because the molecule survives the stomach, both formats are on the market, and they differ in what you can know about them rather than in chemistry.

A vialled lyophilised batch is assayed. The identity and purity figure attach to a lot, and the concentration is set by whoever reconstitutes it. Capsule products are generally sold as supplements, which in Canada means no batch assay is published and the content is whatever the filler put in. If the reason for buying research-grade material is analytical certainty, the vial is the format that supplies it.

What the amount literature actually says

Searches for a 5-Amino-1MQ amount are among the most common on this topic, and the honest answer is unwelcome. Studies in the NNMT inhibitor class report their amounts per kilogram of body mass in mice, over multi-week periods. Those figures do not convert to a human protocol by body-weight scaling, and no controlled human study has established one.

What a researcher does control is concentration, and that is arithmetic rather than guidance. A 50mg vial reconstituted with 2mL of diluent gives 25mg/mL; the same vial with 5mL gives 10mg/mL. A 10mg vial in 2mL gives 5mg/mL. The vial mass and the volume you add are the two numbers in that calculation, and they are the only two numbers this site will give you.

Where the evidence stops

It is animal and cell work. No controlled human trial has examined 5-Amino-1MQ for any endpoint. The metabolic findings are rodent findings in a diet-induced obesity model, and that model is a tool for studying a mechanism, not a smaller version of a person.

The target is clear but the compound is not the best-studied member of its class. NNMT is a defined enzyme with a known reaction, which puts this molecule ahead of several research peptides on mechanism. It is behind them on compound-specific data.

It is not an approved drug anywhere. Not by Health Canada, not by the FDA, not by the EMA, for any use. No regulator has reviewed it. It is supplied as a research chemical for laboratory use, and nothing about its availability implies a safety or efficacy finding by anyone.

Nothing here is medical, dosing, or therapeutic guidance.

Handling and storage

Laboratory technique for a lyophilised cake, which is all this is.

• Sealed and lyophilised: 2–8 °C, protected from light. For storage beyond a few months, −20 °C.
• Reconstitution: bacteriostatic water, added slowly down the vial wall rather than directly onto the powder.
• In solution: refrigerated at 2–8 °C. A reconstituted solution has a materially shorter usable life than sealed lyophilised material, and no beyond-use date is stated here because none has been established for this compound.
• Verification: a batch whose certificate of analysis you cannot independently confirm is a batch of unknown identity. That matters more than usual for a compound this routinely mislabelled at the category level.

Common questions

Is 5-Amino-1MQ a peptide? No. It is a quinolinium small molecule with no amino acid sequence and no peptide bonds. It is catalogued beside peptides because the same suppliers sell it in the same lyophilised vial.

What does it do? In published work it inhibits NNMT, the enzyme that methylates nicotinamide and diverts it away from NAD+ salvage. What that does in a person has not been studied in a controlled trial, so the question has no answer beyond the mouse data.

What is the difference between the 10mg and 50mg vials? The mass of lyophilised material, and nothing else. Same compound, same purity standard, same batch testing. The larger vial gives a wider range of working concentrations from one reconstitution.

Does it work? For NNMT inhibition as a metabolic mechanism in rodents, the preclinical case is reasonably developed. For this specific molecule in humans, there is no controlled evidence at all. Anyone describing results is describing anecdote.

Selected Research References

Cited in the original by author, year and PMID alone, and reproduced as given.

1. Kraus D, et al. 2014. pubmed.ncbi.nlm.nih.gov/24717514
2. Neelakantan H, et al. 2018. pubmed.ncbi.nlm.nih.gov/29155147
3. Kannt A, et al. 2021. pubmed.ncbi.nlm.nih.gov/33668468

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.